Ignite Creation Date:
2024-05-06 @ 3:22 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04616040
Status:
NOT_YET_RECRUITING
Last Update Posted:
2020-11-04
First Post:
2020-10-10
Brief Title:
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
A Non-interventional Registration Study Evaluating the Usage of Camrelizumab in the Treatment of Unresectable Locally AdvancedRecurrent or Metastatic Chinese Patients With Esophageal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial is a multi-center open observational registration study which aims to evaluate the safety and efficacy of Camrelizumab anti-PD-1 antibody in the treatment of Chinese patients with advanced esophageal cancer in the real world
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None